
Merck & Co Inc
NYSE:MRK

Intrinsic Value
The intrinsic value of one
MRK
stock under the Base Case scenario is
111.13
USD.
Compared to the current market price of 104.12 USD,
Merck & Co Inc
is
Undervalued by 6%.
The Intrinsic Value is calculated as the average of the two valuation methods:

Fundamental Analysis
MRK Profitability Score
Profitability Due Diligence
Merck & Co Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Merck & Co Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
MRK Solvency Score
Solvency Due Diligence
Merck & Co Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Merck & Co Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Merck & Co Inc
MRK Capital Structure
Merck & Co Inc
Market Capitalization | 264B USD | |
Total Debt | 28.5B USD | |
Minority Interest | 66M USD | |
Preferred Equity | 0 USD | |
Cash and Equivalents | 11.1B USD | |
Short-Term Investments | 103M USD | |
Enterprise Value | 281B USD |
Wall St
Price Targets
MRK Price Targets Summary
Merck & Co Inc
According to Wall Street analysts, the average 1-year price target for
MRK
is 118.59 USD
with a low forecast of 101 USD and a high forecast of 141.75 USD.
Competitive Landscape
MRK Competitors
Merck & Co Inc
MRK Suppliers & Customers
Merck & Co Inc
Merck & Co Inc has 120 key suppliers from 13 countries and 16 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Merck & Co Inc has 60 key customers from 9 countries and 7 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Ownership
MRK Insider Trading
Buy and sell transactions by insiders
During the last 12 months Merck & Co Inc insiders have not bought any shares, and sold 301M USD worth of shares. The last transaction was made on Feb 6, 2023 by Chattopadhyay Sanat (Exe V-P & Pres. MMD), who sold 9.4M USD worth of MRK shares.
Shareholder Return
MRK Price
Merck & Co Inc
Average Annual Return | 14.85% |
Standard Deviation of Annual Returns | 22.2% |
Max Drawdown | -10% |
Market Capitalization | 264B USD |
Shares Outstanding | 2 542 000 000 |
Percentage of Shares Shorted | 0.77% |
Company Profile

Country
Industry
Market Cap
Dividend Yield
Description
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Kenilworth, New Jersey and currently employs 68,000 full-time employees. The firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company operates through two segments: Pharmaceutical and Animal Health. The firm's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The firm sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
Contact
IPO
Employees
Officers
The intrinsic value of one
MRK
stock under the Base Case scenario is
111.13
USD.
Compared to the current market price of 104.12 USD, Merck & Co Inc is Undervalued by 6%.